Other

Gador S.a.

University of Leiden

Anibal Perez-Lloret

Emilio J A Roldan

Emilio Ja Roldan

Guillermo Vazquez

Sokrates E Papapoulos

Ricardo Boland

This procedure consists in the first stage, of the administration of enough quantity of bisphosphonate preparation during the necessary period of time to acquire a degree of volumetric mineral density of the cortical tissue of application, within the normal range (average.+&#x2212;.1 DS). Then the administration of the bisphosphonate preparation is interrupted in order to enable the development of the sectional momentum of inertia. The length of the second stage can be determined by means of a tomography. That is to say, that the periods of administration or non-administration of the mineralizing agent are defined or controlled by precise osteologic variables and therefore are not fixed. If during the second stage the cortical mineral density drops by 6-10% of the maximum value previously obtained, administration of bisphosphonate preparation should be resumed until the corresponding maximum adjusted value is reached again. The proposed procedure of a period with bisphosphonate followed by another period without the bisphosphonate agent improves fracture resistance, provided that the length of both periods is controlled by defined osteologic variables.

Use of bisphosphonates for the treatment of osteogenesis imperfecta

The present invention relates to novel uses of 1-amino-3-(N,N-dimethylamino)-propylidene-1,1-bisphosphonic acid or any of its soluble salts or any of its hydrates, in particular its use for the manufacture of a medicament for selective modulation of osteoblasts.

Uses of 1-amino-3-(N,N-dimethylamino)-propylidene-1,1-bisphosphonic acid

Growing community of inventors

Buenos Aires, Argentina

Anibal Perez-Lloret